Drug reference

Dihydrotachysterol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1169, 1170

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Acute, chronic, and latent forms of hypocalcaemic tetany due to hypoparathyroidism ▶BY MOUTH ▶Adult: (consult product literature)

PDF page 1169

Safety

Interactions

→Appendix 1: vitamin D substances

PDF page 1169

Side Effects

Abdominal cramps. apathy. dehydration. hypertension. paralysis. renal failure. stupor. urinary disorders. vertigo

PDF page 1169

Renal Impairment

Monitoring Monitor plasma-calcium concentration in renal impairment.

PDF page 1169

Monitoring Requirements

Monitor plasma-calcium concentration in patients receiving high doses.

PDF page 1169

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Oral solution EXCIPIENTS: May contain Arachis (peanut) oil ▶AT10 (Intrapharm Laboratories Ltd) Dihydrotachysterol 250 microgram per 1 ml AT10 250micrograms/ml oral solution sugar-free | 15 ml p £22.87 eiiii F 1143

PDF pages 1169, 1170

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1169

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Dihydrotachysterol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1169, 1170

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Acute, chronic, and latent forms of hypocalcaemic tetany due to hypoparathyroidism ▶BY MOUTH ▶Adult: (consult product literature)

PDF page 1169

Safety

Interactions

→Appendix 1: vitamin D substances

PDF page 1169

Side Effects

Abdominal cramps. apathy. dehydration. hypertension. paralysis. renal failure. stupor. urinary disorders. vertigo

PDF page 1169

Renal Impairment

Monitoring Monitor plasma-calcium concentration in renal impairment.

PDF page 1169

Monitoring Requirements

Monitor plasma-calcium concentration in patients receiving high doses.

PDF page 1169

Dose and formulations

Medicinal Forms

PDF pages 1169, 1170

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1169

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.